Payment overview · 2025
General Payments
$5,642.10
241 reported records · 32 companies
Healthcare provider profile · identity verified
Khalil Innabi, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · YONKERS, NY · NPI 1336184290
Verified facts
What the public records show
CMS Open Payments records show Khalil Innabi, M.D. received $5,642.10 in general payments during 2025 across 241 reported records.
ABBVIE INC. accounted for 19.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 42 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Gemtesa, Jardiance, Linzess, Ozempic, Qulipta, Relistor, Rexulti, Rybelsus, Shingrix, Trelegy Ellipta, Ubrelvy, Voquezna, Vraylar, Zenpep, Ztlido.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 527 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Vraylar by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 227 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 401 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synjardy by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 218 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 264 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rexulti by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 247 claims for Eliquis by this doctor in 2024.
Phathom Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VOQUEZNA as an associated drug or biological on 90302 records involving 33442 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Voquezna by this doctor in 2024.
SCILEX PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZTLido as an associated drug or biological on 6923 records involving 3060 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ztlido by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Relistor by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,085.02 | 19.2% | 44 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $399.86 | 7.1% | 20 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $367.27 | 6.5% | 16 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $357.28 | 6.3% | 20 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $313.67 | 5.6% | 9 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $282.00 | 5.0% | 14 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $279.41 | 5.0% | 14 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $250.66 | 4.4% | 11 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $211.63 | 3.8% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $203.22 | 3.6% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $189.89 | 3.4% | 8 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $181.57 | 3.2% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $175.98 | 3.1% | 9 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $166.72 | 3.0% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $153.34 | 2.7% | 6 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $145.40 | 2.6% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $115.88 | 2.0% | 5 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $115.45 | 2.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $100.85 | 1.8% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $79.27 | 1.4% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $70.94 | 1.3% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $60.74 | 1.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.54 | 1.1% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $58.21 | 1.0% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $41.34 | 0.7% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $35.17 | 0.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.45 | 0.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.93 | 0.4% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $24.43 | 0.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.94 | 0.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.57 | 0.4% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $18.47 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $5,582.10 | 240 |
| Education | $60.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $440.79 | 18 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $399.86 | 20 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $399.86 | 20 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $327.51 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $293.24 | 18 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $282.00 | 14 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $279.41 | 14 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $268.75 | 17 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $266.05 | 13 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $253.67 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $253.18 | 12 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $250.66 | 11 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $209.70 | 9 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $189.89 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $185.26 | 7 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $181.57 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $175.98 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $174.85 | 9 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $163.16 | 8 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $153.34 | 6 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $129.87 | 6 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $115.45 | 1 | 2025 |
Source payment records
|
|||||
| ELYXYB - CELECOXIB Normalized: elyxyb celecoxib |
Drug | SCILEX PHARMACEUTICALS INC. | $110.39 | 6 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $100.85 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $89.62 | 4 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $79.27 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $78.39 | 3 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $77.10 | 3 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $70.94 | 3 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $64.04 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $60.74 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.54 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $59.54 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $45.09 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $41.34 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $35.17 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $24.43 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 161 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 401 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 42 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 224 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 527 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 122 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 51 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 264 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 50 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VOQUEZNA voquezna |
2025 | Voquezna | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 80 | exact normalized | Medicare Part D |
| ZTLido ztlido |
2025 | Ztlido | 2024 | 119 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
161 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
527 | 97 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
80 | 22 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
24 | 15 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
227 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
401 | 57 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
224 | 35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
82 | suppressed by CMS |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
49 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
218 | 207 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
51 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
264 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
224 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
136 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
115 | 16 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
247 | 35 |
| Phathom Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | VOQUEZNA open payments reported associated product |
CMS Open Payments — General Payments 90302 supporting records · 33442 recipient NPIs · example record 1219216983 |
Voquezna · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| SCILEX PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | ZTLido open payments reported associated product |
CMS Open Payments — General Payments 6923 supporting records · 3060 recipient NPIs · example record 1242585247 |
Ztlido · 2024 Exact normalized brand match · 1 Part D row |
119 | 22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
42 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1002 | 194 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 934 | 168 |
| Atorvastatin Calcium | Atorvastatin Calcium | 901 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 743 | 143 |
| Losartan Potassium | Losartan Potassium | 708 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 664 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 637 | 138 |
| Gabapentin | Gabapentin | 624 | 98 |
| Diclofenac Sodium | Diclofenac Sodium | 602 | 188 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 541 | 148 |
| Linzess | Linaclotide | 527 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 469 | 83 |
| Vascepa | Icosapent Ethyl | 456 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 435 | 83 |
| Farxiga | Dapagliflozin Propanediol | 401 | 57 |
| Omeprazole | Omeprazole | 401 | 88 |
| Fluticasone Propionate | Fluticasone Propionate | 370 | 84 |
| Furosemide | Furosemide | 350 | 68 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 295 | 62 |
| Famotidine | Famotidine | 292 | 71 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 292 | 59 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 267 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 264 | 48 |
| Montelukast Sodium | Montelukast Sodium | 254 | 49 |
| Eliquis | Apixaban | 247 | 35 |
| Novolog Flexpen | Insulin Aspart | 244 | 48 |
| Lisinopril | Lisinopril | 242 | 45 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 238 | 31 |
| Metformin Hcl | Metformin Hcl | 231 | 57 |
| Myrbetriq | Mirabegron | 227 | 35 |
| Jardiance | Empagliflozin | 224 | 35 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 218 | 207 |
| Meloxicam | Meloxicam | 216 | 69 |
| Baclofen | Baclofen | 215 | 47 |
| Ezetimibe | Ezetimibe | 199 | 48 |
| Zolpidem Tartrate | Zolpidem Tartrate | 186 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 185 | 35 |
| Januvia | Sitagliptin Phosphate | 182 | 21 |
| Ammonium Lactate | Ammonium Lactate | 177 | 44 |
| Lidocaine | Lidocaine | 175 | 33 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 174 | 25 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 171 | 43 |
| Diclofenac Sodium Er | Diclofenac Sodium | 164 | 53 |
| Creon | Lipase/Protease/Amylase | 161 | 26 |
| Tradjenta | Linagliptin | 160 | 24 |
| Glipizide Er | Glipizide | 156 | 30 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 27 |
| Ranolazine Er | Ranolazine | 146 | 25 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 142 | 33 |
| Carvedilol | Carvedilol | 141 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 139 | 25 |
| Ventolin Hfa | Albuterol Sulfate | 137 | 30 |
| Mounjaro | Tirzepatide | 136 | 19 |
| Meclizine Hcl | Meclizine Hcl | 132 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 127 | 33 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 126 | 27 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 125 | 23 |
| Allopurinol | Allopurinol | 124 | 24 |
| Ozempic | Semaglutide | 122 | 22 |
| Valsartan | Valsartan | 119 | 23 |
| Ztlido | Lidocaine | 119 | 22 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 118 | 27 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 117 | 17 |
| Trulicity | Dulaglutide | 115 | 16 |
| Valacyclovir | Valacyclovir Hcl | 113 | 34 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 113 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 111 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 111 | 24 |
| Folic Acid | Folic Acid | 110 | 28 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 110 | 19 |
| Simvastatin | Simvastatin | 102 | 14 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 100 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 16 |
| Metformin Hcl Er | Metformin Hcl | 99 | 21 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 95 | 31 |
| Alendronate Sodium | Alendronate Sodium | 95 | 27 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 94 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 91 | 15 |
| Finasteride | Finasteride | 90 | 22 |
| Warfarin Sodium | Warfarin Sodium | 89 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 86 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 86 | 66 |
| Propranolol Hcl Er | Propranolol Hcl | 84 | 19 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 82 | 15 |
| Synjardy | Empagliflozin/Metformin Hcl | 82 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 80 | 14 |
| Zenpep | Lipase/Protease/Amylase | 80 | 22 |
| Repatha Sureclick | Evolocumab | 78 | 17 |
| Single Use Swab | Alcohol Antiseptic Pads | 78 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 76 | 20 |
| Tramadol Hcl | Tramadol Hcl | 76 | 11 |
| Azithromycin | Azithromycin | 73 | 57 |
| Atenolol | Atenolol | 72 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 71 | 11 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 70 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 70 | 61 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 69 | 19 |
| Azelastine Hcl | Azelastine Hcl | 68 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 67 | 55 |
| Trazodone Hcl | Trazodone Hcl | 65 | 12 |
| Trintellix | Vortioxetine Hydrobromide | 64 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 13 |
| Jentadueto | Linagliptin/Metformin Hcl | 62 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 62 | 14 |
| Halobetasol Propionate | Halobetasol Propionate | 60 | 19 |
| Nortriptyline Hcl | Nortriptyline Hcl | 60 | suppressed |
| Cefdinir | Cefdinir | 59 | 53 |
| Dexlansoprazole Dr | Dexlansoprazole | 58 | 16 |
| Repatha Syringe | Evolocumab | 58 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 58 | 15 |
| Celecoxib | Celecoxib | 57 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 57 | 11 |
| Roflumilast | Roflumilast | 56 | 15 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 55 | suppressed |
| Twinrix | Hepatitis A And B Vaccine/Pf | 55 | 51 |
| Icosapent Ethyl | Icosapent Ethyl | 54 | 17 |
| Nifedipine Er | Nifedipine | 54 | suppressed |
| Xarelto | Rivaroxaban | 54 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 52 | 14 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 51 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 14 |
| Endocet | Oxycodone Hcl/Acetaminophen | 50 | suppressed |
| Ubrelvy | Ubrogepant | 50 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 49 | 17 |
| Rybelsus | Semaglutide | 49 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | suppressed |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Prednisone | Prednisone | 48 | 31 |
| Alprazolam | Alprazolam | 47 | 12 |
| Entresto | Sacubitril/Valsartan | 46 | suppressed |
| Mirtazapine | Mirtazapine | 46 | 14 |
| Spironolactone | Spironolactone | 46 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 45 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 45 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 44 | suppressed |
| Rexulti | Brexpiprazole | 43 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 43 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 38 |
| Gemtesa | Vibegron | 42 | 14 |
| Hydrocortisone | Hydrocortisone | 42 | 27 |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | suppressed |
| Bystolic | Nebivolol Hcl | 40 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 40 | suppressed |
| Metronidazole | Metronidazole | 40 | 28 |
| Metformin Er Gastric | Metformin Hcl | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 36 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 35 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 35 | 31 |
| Glimepiride | Glimepiride | 35 | suppressed |
| Vraylar | Cariprazine Hcl | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Potassium Chloride | Potassium Chloride | 34 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 33 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 33 | 15 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 33 | suppressed |
| Rivastigmine | Rivastigmine | 33 | suppressed |
| Methimazole | Methimazole | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 16 |
| Nexium | Esomeprazole Magnesium | 31 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Chlorthalidone | Chlorthalidone | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Dexilant | Dexlansoprazole | 28 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 27 | 16 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | 23 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 27 | suppressed |
| Livalo | Pitavastatin Calcium | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 21 |
| Trulance | Plecanatide | 27 | suppressed |
| Edarbi | Azilsartan Medoxomil | 26 | suppressed |
| Lyumjev Kwikpen U-200 | Insulin Lispro-Aabc | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 26 | 15 |
| Nystop | Nystatin | 26 | suppressed |
| Telmisartan | Telmisartan | 26 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 25 | suppressed |
| Prolia | Denosumab | 24 | 15 |
| Clotrimazole | Clotrimazole | 23 | 12 |
| Estradiol | Estradiol | 23 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Adlarity | Donepezil Hcl | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Lactulose | Lactulose | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Calcitriol | Calcitriol | 20 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 20 | suppressed |
| Cycloset | Bromocriptine Mesylate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 19 | suppressed |
| Etodolac Er | Etodolac | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Crestor | Rosuvastatin Calcium | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Movantik | Naloxegol Oxalate | 17 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Naproxen-Esomeprazole Mag | Naproxen/Esomeprazole Mag | 16 | suppressed |
| Qulipta | Atogepant | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Alcohol Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 14 | 13 |
| Nystatin | Nystatin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Toprol Xl | Metoprolol Succinate | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Comfort Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Klonopin | Clonazepam | 12 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Rectiv | Nitroglycerin | 12 | suppressed |
| Relistor | Methylnaltrexone Bromide | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Voquezna | Vonoprazan Fumarate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Novofine Plus | Pen Needle, Diabetic | 11 | suppressed |
| Nyamyc | Nystatin | 11 | suppressed |
| Proscar | Finasteride | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Rapaflo | Silodosin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $5,642.10 · 241 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, Arikayce, BREZTRI, CAPLYTA, CREON, Cologuard Collection Kit, DUPIXENT, Dexcom G6 Transmitter, ELYXYB - CELECOXIB, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, JARDIANCE, KRYSTEXXA, Kerendia, LEQVIO, LINZESS, MYFEMBREE, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, RECORLEV, RELISTOR, REPATHA, REXULTI, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, YUPELRI, ZAVZPRET, ZENPEP, ZORYVE, ZTLido | 33 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error